e0201937a 1 cell therapy liaison meeting january 27, 2006 industry – outline of issues and data...
TRANSCRIPT
E0201937A 1
Cell Therapy Liaison MeetingCell Therapy Liaison MeetingJanuary 27, 2006January 27, 2006
Industry – Outline of Issues and DataIndustry – Outline of Issues and Data
Susan L. Stramer, PhDSusan L. Stramer, PhD
American Red CrossAmerican Red Cross
representing multiple contributing Blood and representing multiple contributing Blood and HPC CentersHPC Centers
Updated March 20, 2006
E0201937A 2
Issue and GoalsIssue and Goals
Mini-pool (MP) NAT for HIV-1 and HCV of HPC Mini-pool (MP) NAT for HIV-1 and HCV of HPC donation samples is not currently acceptable; testing donation samples is not currently acceptable; testing must be performed by individual donation (ID) NAT must be performed by individual donation (ID) NAT (AABB/ISCT teleconference Nov 9, 2005)(AABB/ISCT teleconference Nov 9, 2005)
– Upon communication of this information from Upon communication of this information from AABB (AABB Pulse Points, Nov 29, 2005), blood AABB (AABB Pulse Points, Nov 29, 2005), blood centers converted from MP to ID NAT with the goal centers converted from MP to ID NAT with the goal of qualification of MP NAT for HPC donations in of qualification of MP NAT for HPC donations in the futurethe future
• Multiple communications within organizations to Multiple communications within organizations to ensure compliance; e.g., ARC, Dec 7, 2005; ensure compliance; e.g., ARC, Dec 7, 2005; AATB, Nov 17, 2005AATB, Nov 17, 2005
E0201937A 3
Issues and GoalsIssues and Goals ““Specimens from other living donors (except whole Specimens from other living donors (except whole
blood, blood, blood componentsblood components or source plasma) and from or source plasma) and from cadaveric donors should be tested using the cadaveric donors should be tested using the individual donor testing method only” individual donor testing method only” – (GP insert, version IN0076-01 REV A)(GP insert, version IN0076-01 REV A)
Definition of a blood component: “product containing Definition of a blood component: “product containing a part of human blood separated by physical or a part of human blood separated by physical or mechanical means” (21 CFR 1271.3(i))mechanical means” (21 CFR 1271.3(i))
– Interpretation was that donations from HPC Interpretation was that donations from HPC donors (peripheral blood stem cells, maternal cord donors (peripheral blood stem cells, maternal cord blood, bone marrow) meet this criteriablood, bone marrow) meet this criteria
E0201937A 4
Issues and GoalsIssues and Goals Analysis in support of MP NAT Analysis in support of MP NAT
prospectively/retrospectively by comparing prospectively/retrospectively by comparing frequency of infectious disease markers in HPC frequency of infectious disease markers in HPC donations to those of donations of whole blood donations to those of donations of whole blood (autologous and allogeneic FT/RPT donations; i.e., (autologous and allogeneic FT/RPT donations; i.e., those already approved for MP NAT)those already approved for MP NAT)
– Data to be shared with FDA but will be submitted Data to be shared with FDA but will be submitted to manufacturers so that their package inserts may to manufacturers so that their package inserts may be modified to include a claim for MP NAT of be modified to include a claim for MP NAT of HPC donations (assuming the data support such a HPC donations (assuming the data support such a modification)modification)
E0201937A 5
Points to ConsiderPoints to Consider NAT clinical trials, and prospective use of the licensed NAT clinical trials, and prospective use of the licensed
assays, have included samples from the following assays, have included samples from the following donations in context of MP NAT: allogeneic FT/RPT, donations in context of MP NAT: allogeneic FT/RPT, autologous, pheresis, HPCsautologous, pheresis, HPCs– All samples from heart-beating donors meeting the sample All samples from heart-beating donors meeting the sample
suitability criteria of the clinical protocols/licensed inserts suitability criteria of the clinical protocols/licensed inserts were considered suitable for pooling and testingwere considered suitable for pooling and testing
– Only donations of organ and tissue donors have been tested by Only donations of organ and tissue donors have been tested by ID NAT due to sample suitability issues; testing frequently ID NAT due to sample suitability issues; testing frequently occurs in separate laboratories to segregate from samples occurs in separate laboratories to segregate from samples tested by MP NATtested by MP NAT• Hemodilution/hemolysis (not included in this presentation)Hemodilution/hemolysis (not included in this presentation)
– At request of FDA, separate analysis was performed post-At request of FDA, separate analysis was performed post-licensure to include volunteer source pheresis; insert modified licensure to include volunteer source pheresis; insert modified based on analyzed databased on analyzed data
E0201937A 6
Points to Consider-Points to Consider-False PositivityFalse Positivity Impact of ID NAT on lost donors/productsImpact of ID NAT on lost donors/products
– MP involves two rounds of testing in contrast to ID NATMP involves two rounds of testing in contrast to ID NAT
– False positive rates since FDA licensure:False positive rates since FDA licensure:
• 1:40,000-1:100,000 (0.001-0.0025%) for MP NAT by site1:40,000-1:100,000 (0.001-0.0025%) for MP NAT by site
• 1:555-1:2150 for ID NAT by lot (0.08-0.18%; mean 1:555-1:2150 for ID NAT by lot (0.08-0.18%; mean 0.13%)0.13%)
• 32-180X (80X mean) higher reactive rate for ID NAT32-180X (80X mean) higher reactive rate for ID NAT
– Decrease in specificity of 99%Decrease in specificity of 99%
• Additional loss of 130 donors/donations for every 100,000 Additional loss of 130 donors/donations for every 100,000 testedtested
– Result is the loss of valuable, sometimes irreplaceable Result is the loss of valuable, sometimes irreplaceable donors/donationsdonors/donations
E0201937A 7
Points to Consider-Points to Consider-CostCost
Impact of ID NAT on costImpact of ID NAT on cost
– Additional $3-5 per donation for ID vs MP Additional $3-5 per donation for ID vs MP NATNAT • Current price approx $10.00 per MP NAT; Current price approx $10.00 per MP NAT;
additional $300,000-$500,000 for every additional $300,000-$500,000 for every 100,000 donations for ID NAT100,000 donations for ID NAT
• One manufacturer (GP/Chiron) has agreed One manufacturer (GP/Chiron) has agreed not to increase pricing until March 2006; then not to increase pricing until March 2006; then price will increaseprice will increase
E0201937A 8
Points to Consider-Points to Consider-LogisticsLogistics Impact of ID NAT on logisticsImpact of ID NAT on logistics
– Up to 8000 samples/day arrive in a consolidated Up to 8000 samples/day arrive in a consolidated testing labtesting lab
– No automated systems to sort samples; performed No automated systems to sort samples; performed manually based on visual examination of each tube manually based on visual examination of each tube and sorting based on WBN codes on tube labelsand sorting based on WBN codes on tube labels
• Procedures/processes developed to identify and test Procedures/processes developed to identify and test HPC donations by ID NATHPC donations by ID NAT
– Error prone; what is impact of an HPC inadvertently Error prone; what is impact of an HPC inadvertently tested by MP NAT?tested by MP NAT?
– Increase in staff needed for sorting/testing/QCIncrease in staff needed for sorting/testing/QC
• Cost not captured in this presentationCost not captured in this presentation
E0201937A 9
Analysis GoalsAnalysis Goals To determine the infectious disease marker To determine the infectious disease marker
prevalence/incidence rates for donations of prevalence/incidence rates for donations of Hematopoietic Progenitor Cells (HPC) donors Hematopoietic Progenitor Cells (HPC) donors to to qualify these donations for MP NAT by qualify these donations for MP NAT by demonstrating equivalence to blood donation demonstrating equivalence to blood donation types already included in the intended use types already included in the intended use statements for licensed NAT assays, and prove statements for licensed NAT assays, and prove that the risks associated with MP NAT as that the risks associated with MP NAT as compared to ID NAT for HPC donations are no compared to ID NAT for HPC donations are no greater than the difference between MP and ID greater than the difference between MP and ID NAT for donations of whole bloodNAT for donations of whole blood
E0201937A 10
Analysis MethodsAnalysis Methods Prevalence of HIV, HCV and HBV determined by Prevalence of HIV, HCV and HBV determined by
antibody or antigen confirmed positive rates (using antibody or antigen confirmed positive rates (using specific confirmatory tests or NATspecific confirmatory tests or NAT, or repeat reactivity , or repeat reactivity if none of the above exist, such as anti-HBc)if none of the above exist, such as anti-HBc)
IncidenceIncidence of each agent (including WNV) will be of each agent (including WNV) will be determined determined by NAT yieldby NAT yield (antibody/antigen negative) (antibody/antigen negative)
Included in the analysis are the test results for samples Included in the analysis are the test results for samples of donations of of donations of HPC donors collected from HPC donors collected from geographically distinct US collection facilities from the geographically distinct US collection facilities from the time of NAT licensure to the end of 2005time of NAT licensure to the end of 2005
Results from screening ARC whole blood donations Results from screening ARC whole blood donations from a similar period of time serve as the controlfrom a similar period of time serve as the control
E0201937A 11
Analysis MethodsAnalysis Methods Spreadsheet distributed through AABB and ABC to Spreadsheet distributed through AABB and ABC to
collecting and testing sites (Nov 30, 2005)collecting and testing sites (Nov 30, 2005) Requested results for all infectious disease testing Requested results for all infectious disease testing
including: anti-HIV-1/2, HIV-1 NAT, anti-HCV, including: anti-HIV-1/2, HIV-1 NAT, anti-HCV, HCV NAT, HBsAg, anti-HBc, HBV NAT and HCV NAT, HBsAg, anti-HBc, HBV NAT and WNV, as availableWNV, as available– FDA licensed tests or testing using approved FDA licensed tests or testing using approved
investigational protocols/reagentsinvestigational protocols/reagents Break out requested by HPC typeBreak out requested by HPC type
– Peripheral blood stem cells (PS)Peripheral blood stem cells (PS)– Bone marrow (B)Bone marrow (B)– Maternal cord blood (C)Maternal cord blood (C)
E0201937A 12
Analysis MethodsAnalysis Methods Data submitted to ARC to prepare a consolidated Data submitted to ARC to prepare a consolidated
line listing and to perform analysis vs a control line listing and to perform analysis vs a control population already approved for MP NATpopulation already approved for MP NAT– ARC donor population: autologous and allogeneic ARC donor population: autologous and allogeneic
donations from 4/1/04-3/31/05donations from 4/1/04-3/31/05
• 6.55 million allogeneic and 1.066 million 6.55 million allogeneic and 1.066 million autologous donationsautologous donations
Data included in the analysis represent all Data included in the analysis represent all donations that meet the donations that meet the licensed/investigational package insert sample licensed/investigational package insert sample suitability requirementssuitability requirements
E0201937A 13
Data Collection from HPC SitesData Collection from HPC Sites Data received from Data received from 10 organizations10 organizations, ,
many with multiple organizations many with multiple organizations representedrepresented– e.g., NMDP has 72 submitting centers with e.g., NMDP has 72 submitting centers with
34 different testing sites34 different testing sites
171,619 HPC submitted data points 171,619 HPC submitted data points having both NAT and serology results having both NAT and serology results (next slide)(next slide)– 139,654 HPC samples associated with a 139,654 HPC samples associated with a
donation (removal of 31,965 “unknown donation (removal of 31,965 “unknown types” not associated with a donation)types” not associated with a donation)
E0201937A 14
Donations Analyzed-Donations Analyzed-updateupdate 3/20/063/20/06SiteSite Samples Samples
SubmittedSubmittedResults with Results with
NATNATResults with NAT Results with NAT
and Serologyand Serology
BSLBSL 71,00671,006 57,69757,697 57,68257,682
ARCARC 31,78131,781 29,18429,184 14,91714,917
BergenBergen 181181 181181 181181
PSBCPSBC 22912291 21132113 21132113
BonfilsBonfils 27892789 804804 803803
NMDPNMDP 54,25754,257 45,86545,865 45,80645,806
StemCyteStemCyte 15,44115,441 15,44115,441 15,44115,441
CHOCCHOC 20302030 20302030 20302030
FBSFBS 10,28310,283 10,28310,283 10,26910,269
CIRBCCIRBC 23,25823,258 22,37722,377 22,37722,377
TOTALTOTAL 213,268213,268 185,975185,975 171,619171,619
E0201937A 15
Submissions from All Submitting Sites Combined Submissions from All Submitting Sites Combined by HPC Donation Type; Complete Data for by HPC Donation Type; Complete Data for
N=139,654 N=139,654 (3/20/06)(3/20/06)
HPC TypeHPC Type FrequencyFrequency PercentPercent
UnknownUnknown 43544354 3.13.1
Bone marrowBone marrow 71447144 5.15.1
Bone Bone marrow/PSmarrow/PS
676676 0.50.5
Cord bloodCord blood 114,070114,070 81.781.7
PSPS 13,41013,410 9.69.6
E0201937A 16
Frequencies of Marker Positives in Whole Blood DonationsFrequencies of Marker Positives in Whole Blood DonationsARC; 4/1/04-3/31/05ARC; 4/1/04-3/31/05
6.55 million Allogeneic and 1.066 million Autologous Donations6.55 million Allogeneic and 1.066 million Autologous Donations
Combined Combined Donations per Donations per
10,00010,000
Allogeneic Allogeneic Donations per Donations per
10,00010,000
Autologous Autologous Donations per Donations per
10,00010,000
Anti-HIVAnti-HIV TotalTotal 0.3050.305 0.2630.263 2.9082.908
FTFT 1.1421.142 1.0251.025 3.9573.957
RPTRPT 0.1210.121 0.1000.100 2.0482.048
RangeRange 0.100-3.9570.100-3.957
HIV NATHIV NAT TotalTotal 0.00750.0075 0.00760.0076 00
FTFT 0.01670.0167 0.01740.0174 00
RPTRPT 0.00550.0055 0.00560.0056 00
RangeRange 0-0.01740-0.0174
E0201937A 17
Frequencies of Marker Positives in Whole Blood DonationsFrequencies of Marker Positives in Whole Blood DonationsARC; 4/1/04-3/31/05ARC; 4/1/04-3/31/05
6.55 million Allogeneic and 1.066 million Autologous Donations6.55 million Allogeneic and 1.066 million Autologous Donations
Combined Combined Donations per Donations per
10,00010,000
Allogeneic Allogeneic Donations per Donations per
10,00010,000
Autologous Autologous Donations per Donations per
10,00010,000
Anti-HCVAnti-HCV TotalTotal 5.1035.103 3.4833.483 104.67104.67
FTFT 22.3322.33 18.3118.31 118.71118.71
RPTRPT 1.3201.320 0.3240.324 93.1793.17
RangeRange 0.324-118.710.324-118.71
HCV NATHCV NAT TotalTotal 0.0420.042 0.0400.040 0.1880.188
FTFT 0.1170.117 0.1040.104 0.4170.417
RPTRPT 0.0260.026 0.0260.026 00
RangeRange 0-0.4170-0.417
E0201937A 18
Frequencies of Marker Positives in Whole Blood DonationsFrequencies of Marker Positives in Whole Blood DonationsARC; 4/1/04-3/31/05ARC; 4/1/04-3/31/05
6.55 million Allogeneic and 1.066 million Autologous Donations6.55 million Allogeneic and 1.066 million Autologous Donations
Combined Combined Donations per Donations per
10,00010,000
Allogeneic Allogeneic Donations per Donations per
10,00010,000
Autologous Autologous Donations per Donations per
10,00010,000
Anti-HBcAnti-HBc TotalTotal 35.6135.61 29.6629.66 401.34401.34
FTFT 121.32121.32 107.96107.96 441.74441.74
RPTRPT 16.7916.79 12.9812.98 368.25368.25
RangeRange 12.98-441.7412.98-441.74
HBsAgHBsAg TotalTotal 1.4921.492 1.2871.287 14.1614.16
FTFT 6.9546.954 6.4976.497 17.9117.91
RPTRPT 0.3040.304 0.1760.176 12.1212.12
RangeRange 0.176-17.910.176-17.91
E0201937A 19
Frequencies of Marker Positives in Whole Blood DonationsFrequencies of Marker Positives in Whole Blood DonationsARC; 4/1/04-3/31/05ARC; 4/1/04-3/31/05
6.55 million Allogeneic and 1.066 million Autologous Donations6.55 million Allogeneic and 1.066 million Autologous Donations
Combined Combined Donations per Donations per
10,00010,000
Allogeneic Allogeneic Donations per Donations per
10,00010,000
Autologous Autologous Donations per Donations per
10,00010,000
WNVWNV TotalTotal 0.1220.122 0.1170.117 0.3750.375
FTFT 0.1330.133 0.1130.113 0.6240.624
RPTRPT 0.1190.119 0.1180.118 0.1710.171
RangeRange 0.113-0.6240.113-0.624
E0201937A 20
Frequencies of Marker Positives in HPC DonationsFrequencies of Marker Positives in HPC DonationsAll Submitting Sites; Date of Licensure-12/31/05All Submitting Sites; Date of Licensure-12/31/05139,654139,654 HPC Donations vs Control Donations HPC Donations vs Control Donations
Anti-HIV per 10,000 Anti-HIV per 10,000 donationsdonations
HIV-1 NAT per HIV-1 NAT per 10,000 donations10,000 donations
HPC TotalHPC Total 0.360.36 00
Bone Marrow/PSBone Marrow/PS 0.000.00 00
Cord Blood onlyCord Blood only 0.180.18 00
PS onlyPS only 2.242.24 00
UnknownUnknown 00 00
HPC RangeHPC Range 0-2.240-2.24 NANA
Control RangeControl Range 0.10-3.960.10-3.96 0-0.0170-0.017
E0201937A 21
Frequencies of Marker Positives in HPC DonationsFrequencies of Marker Positives in HPC DonationsAll Submitting Sites; Date of Licensure-12/31/05All Submitting Sites; Date of Licensure-12/31/05139,654 139,654 HPC Donations vs Control DonationsHPC Donations vs Control Donations
Anti-HCV per Anti-HCV per 10,000 donations10,000 donations
HCV NAT per HCV NAT per 10,000 donations10,000 donations
HPC TotalHPC Total 15.4015.40 0.930.93
Bone Marrow/PSBone Marrow/PS 33.2433.24 1.281.28
Cord Blood onlyCord Blood only 14.1114.11 0.960.96
PS onlyPS only 20.8920.89 00
UnknownUnknown 00 2.302.30
HPC RangeHPC Range 0-33.240-33.24 0-2.300-2.30
Control RangeControl Range 0.32-118.710.32-118.71 0-0.4170-0.417
E0201937A 22
Frequencies of Marker Positives in HPC DonationsFrequencies of Marker Positives in HPC DonationsAll Submitting Sites; Date of Licensure-12/31/05All Submitting Sites; Date of Licensure-12/31/05109,286 109,286 HPC Donations vs Control DonationsHPC Donations vs Control Donations
Anti-HBc per Anti-HBc per 10,000 donations10,000 donations
HBsAg per HBsAg per 10,000 10,000
donationsdonations
HBV NAT per HBV NAT per 10,000 10,000
donationsdonations
HPC TotalHPC Total 274.42274.42 25.4425.44 00
Bone Bone Marrow/PSMarrow/PS
132.97132.97 9.019.01 00
Cord Blood Cord Blood onlyonly
301.44301.44 28.8828.88 00
PS onlyPS only 100.0100.0 1.591.59 00
UnknownUnknown 87.3087.30 2.302.30 00
HPC RangeHPC Range 87.30-301.4487.30-301.44 1.59-28.881.59-28.88 00
Control Control RangeRange
12.98-441.7412.98-441.74 0.176-17.910.176-17.91 nana
E0201937A 23
Frequencies of Marker Positives in HPC DonationsFrequencies of Marker Positives in HPC DonationsAll Submitting Sites; Date of Licensure-12/31/05All Submitting Sites; Date of Licensure-12/31/05
38,05238,052 HPC Donations vs Control Donations HPC Donations vs Control Donations
WNV NAT per 10,000 donationsWNV NAT per 10,000 donations
HPC TotalHPC Total 0.790.79
Bone Bone Marrow /PSMarrow /PS
00
Cord Blood Cord Blood onlyonly
00
PS onlyPS only 1.891.89
UnknownUnknown 5.515.51
HPC RangeHPC Range 0-5.510-5.51
Control RangeControl Range 0.113-0.6240.113-0.624
E0201937A 24
Comparisons by MarkerComparisons by MarkerHPC vs Control Sample Sets Analyzing Controls as: HPC vs Control Sample Sets Analyzing Controls as:
Combined, Allogeneic and AutologousCombined, Allogeneic and Autologous HIVHIV
– Antibody => only significant difference observed was Antibody => only significant difference observed was autologous > HPCsautologous > HPCs• 2.91 autologous vs 0.36 HPCs/10,000 donations2.91 autologous vs 0.36 HPCs/10,000 donations
– NAT => no HIV yield samplesNAT => no HIV yield samples HCVHCV
– Antibody => significant differences observed where Antibody => significant differences observed where autologous > all othersautologous > all others• 105 autologous vs 15.40 HPCs/10,000 donations105 autologous vs 15.40 HPCs/10,000 donations
– NAT => no significant differences between autologous NAT => no significant differences between autologous and HPC donationsand HPC donations• Confirmatory data lacking for five of thirteen HCV Confirmatory data lacking for five of thirteen HCV
NAT yield HPC donationsNAT yield HPC donations
E0201937A 25
Comparisons by MarkerComparisons by MarkerHPC vs Control Sample Sets Analyzing Controls as: HPC vs Control Sample Sets Analyzing Controls as:
Combined, Allogeneic and AutologousCombined, Allogeneic and Autologous HBVHBV
– Antibody => significant differences where autologous highestAntibody => significant differences where autologous highest• 30 allogeneic, 36 combined, 274 HPCs vs 401 30 allogeneic, 36 combined, 274 HPCs vs 401
autologous/10,000 donationsautologous/10,000 donations– HBsAg => significant differences where HPC highestHBsAg => significant differences where HPC highest
• 1.29 allogeneic, 1.49 combined, 14.16 autologous vs 1.29 allogeneic, 1.49 combined, 14.16 autologous vs 25.44 HPCs/10,000 donations25.44 HPCs/10,000 donations
• Impact of Ortho 3 false positivity unknownImpact of Ortho 3 false positivity unknown– 70% (196/278) of HPC positives Ortho 3 confirmed70% (196/278) of HPC positives Ortho 3 confirmed
– NAT => no yield samplesNAT => no yield samples
WNVWNV– NAT => no significant differences between any groupsNAT => no significant differences between any groups
• Confirmatory data lacking for two of three WNV NAT Confirmatory data lacking for two of three WNV NAT yield HPC donationsyield HPC donations
E0201937A 26
Comparison of Prevalence Rates/10,000 donationsComparison of Prevalence Rates/10,000 donations
Combined Combined Whole Whole BloodBlood
Autologous Autologous Whole Whole BloodBlood
Combined Combined HPCsHPCs
Anti-HIVAnti-HIV 0.300.30 2.91*2.91* 0.360.36
Anti-HCVAnti-HCV 5.105.10 104.7*104.7* 15.4015.40
Anti-HBcAnti-HBc 35.6135.61 401.3*401.3* 274.4274.4
HBsAgHBsAg 1.491.49 14.1614.16 25.44*,**25.44*,**
*p<0.05 for one or multiple comparisons; ** Ortho System 3
E0201937A 27
Summary and ConclusionsSummary and Conclusions Overall comparison of prevalence rates shows no Overall comparison of prevalence rates shows no
difference between control groups and HPC difference between control groups and HPC donationsdonations– 3 of 4 cases autologous higher, 1 case of 4, HPC higher 3 of 4 cases autologous higher, 1 case of 4, HPC higher
where Ortho 3 used only for HPC groupwhere Ortho 3 used only for HPC group
No significant differences in incidence (as No significant differences in incidence (as determined by NAT yield) observed between control determined by NAT yield) observed between control groups and HPC donationsgroups and HPC donations– With HPC NAT-reactives mostly unconfirmed With HPC NAT-reactives mostly unconfirmed
No additional risk of MP NAT for HPC donations as No additional risk of MP NAT for HPC donations as compared to the control groups for which MP NAT compared to the control groups for which MP NAT occursoccurs
E0201937A 28
Next StepsNext Steps
Share presentation with test kit Share presentation with test kit manufacturersmanufacturers
Prepare line listings by submitting Prepare line listings by submitting site/donation type, including analysis versus site/donation type, including analysis versus control population and provide to the NAT control population and provide to the NAT test kit manufacturers for labeling test kit manufacturers for labeling modifications to allow MP NAT of HPC modifications to allow MP NAT of HPC donations donations
Next series of slides highlight the Next series of slides highlight the individual manufacturers’ data (3/20/06)individual manufacturers’ data (3/20/06)